3.03 -0.07 (-2.24%)
AVNR
| Trade AVNR now with |
|
Stock Details
Last Trade:3.03 Change:-0.07 (-2.24%) Prev Close:3.10 Open: 3.13 Days Range:3.01 – 3.18 52 Week Range: 1.77 - 4.80 Volume:946647 P/E: N/AEPS:-0.51
View AllRecent Alerts 02/10/12
Recent Alert on 02/08/12 at 9:48am
Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Good Nuedexta Trends Continues, Phase 2 Progress
Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Good Nuedexta Trends Continues, Phase 2 Progress
Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR) price target of $6.00. Analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta’s steady, continued growth, robust peak sales estimate. Nuedexta is... Read More
Recent Alert on 02/08/12 at 9:08am
Avanir (AVNR) Reports Publication of Superior Results from AVP-923 Phase III Dosage Study
Avanir (AVNR) Reports Publication of Superior Results from AVP-923 Phase III Dosage Study
Recent Alert on 02/08/12 at 9:08am
Avanir (AVNR) Reports Publication of Superior Results from AVP-923 Phase III Dosage Study
Avanir (AVNR) Reports Publication of Superior Results from AVP-923 Phase III Dosage Study
Recent Alert on 02/07/12 at 4:53pm
Avanir Pharmaceuticals, Inc. (AVNR) Posts Better-Than-Expected Q1 Results
Avanir Pharmaceuticals, Inc. (AVNR) Posts Better-Than-Expected Q1 Results
Recent Alert on 02/06/12 at 5:24pm
Trading Radar for 02/07: Coca-Cola (KO), Disney (DIS), BP plc (BP), Open Table (OPEN), Lannett (LCI) Report
Trading Radar for 02/07: Coca-Cola (KO), Disney (DIS), BP plc (BP), Open Table (OPEN), Lannett (LCI) Report
View AllRecent Press Releases
Press Release on 02/08/12 at 9:00am
Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
Press Release on 02/07/12 at 4:00pm
Avanir Pharmaceuticals Reports Fiscal 2012 First Quarter Financial and Business Results
Avanir Pharmaceuticals Reports Fiscal 2012 First Quarter Financial and Business Results
View AllRecent SEC Filings
SEC Filing on 02/08/12 at 3:32pm
Form SC 13G/A AVANIR PHARMACEUTICALS, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SC 13G/A AVANIR PHARMACEUTICALS, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
SEC Filing on 02/07/12 at 12:52pm
Form SC 13G/A AVANIR PHARMACEUTICALS, Filed by: INGALLS & SNYDER LLC
Form SC 13G/A AVANIR PHARMACEUTICALS, Filed by: INGALLS & SNYDER LLC
View AllRecent Blog Posts
Blog Posts on 01/15/12 at 4:50am
All Objectives Met In The $50k Challenge: 10.3% Return In Less Than 5 Days
All Objectives Met In The $50k Challenge: 10.3% Return In Less Than 5 Days